Cumulative drug approval applications under priority review (annual)
Total cumulative number of drug approval applications granted priority review status since program inception.
Unit Count Industry Pharmaceuticals
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Cumulative drug approval applications under priority review (annual)
China, 2020–2024
Every record
All records
1 record · 1 region · 2020–2024
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs | NMPA | — | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Cumulative drug approval applications under priority review (annual). Retrieved from https://statorigin.org/indicators/cumulative-drug-approval-applications-under-priority-review-annual